{
  "release_id": "a25293eeae6350fb",
  "id": "cardio:fenofibrate",
  "owner": "cardio",
  "kind": "drug",
  "slug": "fenofibrate",
  "name": "Fenofibrate",
  "aliases": [
    "Antara"
  ],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "Fenofibrate is a fibrate, a cholesterol and triglyceride medicine taken by mouth. The US label read, for Antara capsules, lists two uses in adults, as an add-on to diet: lowering triglycerides in severe hypertriglyceridemia, and lowering raised LDL cholesterol in primary hyperlipidemia when the recommended LDL-lowering treatment cannot be used. The label also says fenofibrate did not reduce coronary heart disease illness and death in two large randomized trials of people with type 2 diabetes.",
  "summary_technical": "RxNorm ingredient 8703; UNII U202363UOS. MeSH descriptor D011345 is Fenofibrate. RxClass lists the FDA chemical class Fibric Acids and the established pharmacologic class Peroxisome Proliferator-activated Receptor alpha Agonist; the record is filed under the class page Fibrates on that evidence. The label read is the Lupin Pharmaceuticals, Inc. label for Antara capsules, application NDA021695, effective 2025-10-01 in openFDA, the label the class page already uses. The plan row pointed at a generic label (ANDA200920); the Antara brand label replaces it. Fenofibrate tablets, delayed-release capsules and the choline fenofibrate products have other labels and labelled uses and were not read. This page records the label indications, the label's statement on coronary heart disease outcomes and the mechanism sentence only: no dose is given.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-11-18",
  "last_evidence_check": "2026-11-18",
  "next_review_due": null,
  "identifiers": [
    {
      "scheme": "rxnorm",
      "value": "8703",
      "normalized_value": "8703",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    },
    {
      "scheme": "unii",
      "value": "U202363UOS",
      "normalized_value": "U202363UOS",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    },
    {
      "scheme": "mesh",
      "value": "D011345",
      "normalized_value": "D011345",
      "match": "exact",
      "version": "read 2026-11-18",
      "label": null,
      "from_source": false
    }
  ],
  "navigation": {
    "cardio": {
      "system": [
        "metabolism"
      ],
      "condition-area": [
        "risk-and-prevention"
      ]
    }
  },
  "payload": {
    "level": "substance",
    "mechanism": "The Antara label says the active moiety is fenofibric acid, which increases lipolysis and the elimination of triglyceride-rich particles from plasma."
  },
  "content_digest": "785a4fd9ad4dfee9413cc37105a5310476aa666164bfa9777fa03058d7d3c14f",
  "review": {
    "content_digest": "785a4fd9ad4dfee9413cc37105a5310476aa666164bfa9777fa03058d7d3c14f",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-fenofibrate-label-indications",
      "owner": "cardio",
      "subject_entity_id": "cardio:fenofibrate",
      "category": "descriptive",
      "statement": "The US label of Antara (fenofibrate capsules, Lupin Pharmaceuticals, Inc., application NDA021695; the version dated 2025-10-01 in openFDA) lists two uses as adjunctive therapy to diet in adults: reducing triglyceride levels in severe hypertriglyceridemia, and reducing elevated LDL cholesterol in primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible. The label also says fenofibrate did not reduce coronary heart disease morbidity and mortality in two large randomized controlled trials of patients with type 2 diabetes mellitus. It calls the medicine a PPAR alpha agonist.",
      "context": {
        "id": "cardio:ctx-fda-antara-label-us",
        "label": "Adults with severe hypertriglyceridemia or primary hyperlipidemia, as described in the US label of Antara fenofibrate capsules",
        "recipient": "adult",
        "population": "Adults with severe hypertriglyceridemia, and adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible, as the indications section of the label states.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Adults, as the label states",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Adults with severe hypertriglyceridemia",
            "Adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible"
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim records what one US label says the medicine is indicated for and how it describes the medicine. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Fenofibrate products differ in form and in labelled uses; only the Antara capsule label was read. The label passages read state no age range except where the claim says adults. Contraindications, warnings, interactions, use in pregnancy and in children, and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.",
      "editorial_state": "draft",
      "checked_at": "2026-11-18",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "context",
          "locator": "results[0].openfda.application_number[0]",
          "applicability_note": "Application number of the label read.",
          "snapshot": {
            "id": "cardio:openfda-label-antara-2026-11-18",
            "retrieved_at": "2026-11-18T20:11:53Z",
            "content_hash": "ef308cd78aef6355d860914c0e0c959deebd9ef921a1bca33ac7dea73a57a271",
            "source_effective_date": "2025-10-01",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-antara",
            "source_type": "regulator",
            "title": "openFDA drug label record for Antara (fenofibrate capsules), Lupin Pharmaceuticals, Inc. label: description and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%2224790a18-0291-4b88-a724-acac43b616ce%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 24790a18-0291-4b88-a724-acac43b616ce (manufacturer Lupin Pharmaceuticals, Inc., application NDA021695), returned on 2026-11-18. The label text is dated 2025-10-01 (effective_time). Other openFDA fenofibrate and gemfibrozil labels are mostly repackager or generic labels and were not used; no brand-name gemfibrozil label was returned.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k06-openfda-label-antara.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read.",
          "snapshot": {
            "id": "cardio:openfda-label-antara-2026-11-18",
            "retrieved_at": "2026-11-18T20:11:53Z",
            "content_hash": "ef308cd78aef6355d860914c0e0c959deebd9ef921a1bca33ac7dea73a57a271",
            "source_effective_date": "2025-10-01",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-antara",
            "source_type": "regulator",
            "title": "openFDA drug label record for Antara (fenofibrate capsules), Lupin Pharmaceuticals, Inc. label: description and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%2224790a18-0291-4b88-a724-acac43b616ce%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 24790a18-0291-4b88-a724-acac43b616ce (manufacturer Lupin Pharmaceuticals, Inc., application NDA021695), returned on 2026-11-18. The label text is dated 2025-10-01 (effective_time). Other openFDA fenofibrate and gemfibrozil labels are mostly repackager or generic labels and were not used; no brand-name gemfibrozil label was returned.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k06-openfda-label-antara.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0]",
          "applicability_note": "Label passage quoted in the research quote table (FEN-LB-04, FEN-LB-05, FEN-LB-06).",
          "snapshot": {
            "id": "cardio:openfda-label-antara-2026-11-18",
            "retrieved_at": "2026-11-18T20:11:53Z",
            "content_hash": "ef308cd78aef6355d860914c0e0c959deebd9ef921a1bca33ac7dea73a57a271",
            "source_effective_date": "2025-10-01",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-antara",
            "source_type": "regulator",
            "title": "openFDA drug label record for Antara (fenofibrate capsules), Lupin Pharmaceuticals, Inc. label: description and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%2224790a18-0291-4b88-a724-acac43b616ce%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 24790a18-0291-4b88-a724-acac43b616ce (manufacturer Lupin Pharmaceuticals, Inc., application NDA021695), returned on 2026-11-18. The label text is dated 2025-10-01 (effective_time). Other openFDA fenofibrate and gemfibrozil labels are mostly repackager or generic labels and were not used; no brand-name gemfibrozil label was returned.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k06-openfda-label-antara.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].description[0]",
          "applicability_note": "Label passage quoted in the research quote table (FEN-LB-07).",
          "snapshot": {
            "id": "cardio:openfda-label-antara-2026-11-18",
            "retrieved_at": "2026-11-18T20:11:53Z",
            "content_hash": "ef308cd78aef6355d860914c0e0c959deebd9ef921a1bca33ac7dea73a57a271",
            "source_effective_date": "2025-10-01",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-antara",
            "source_type": "regulator",
            "title": "openFDA drug label record for Antara (fenofibrate capsules), Lupin Pharmaceuticals, Inc. label: description and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%2224790a18-0291-4b88-a724-acac43b616ce%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 24790a18-0291-4b88-a724-acac43b616ce (manufacturer Lupin Pharmaceuticals, Inc., application NDA021695), returned on 2026-11-18. The label text is dated 2025-10-01 (effective_time). Other openFDA fenofibrate and gemfibrozil labels are mostly repackager or generic labels and were not used; no brand-name gemfibrozil label was returned.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k06-openfda-label-antara.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "b67bd6b61e0f1336d095cb82c90ce7aef30522e8b71cc4e84fd0834870a5b97d",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-fenofibrate-label-indications.json"
    }
  ],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "subtype_of",
        "label": "Fenofibrate belongs to the fibric acids (FDA chemical class in RxClass) and is a PPAR alpha agonist",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:fibrates",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:rxclass-8703-2026-11-18",
          "locator": "rxclassDrugInfoList.rxclassDrugInfo[1].rxclassMinConceptItem.className"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label lists reducing triglycerides in adults with severe hypertriglyceridemia as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:hypertriglyceridemia",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-fenofibrate-label-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label lists reducing elevated LDL-C in adults with primary hyperlipidemia, when recommended LDL-C lowering therapy cannot be used, as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:dyslipidemia",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-fenofibrate-label-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "part_of",
        "label": "Files under this front",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:front-medicines",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": []
  },
  "page_path": "drugs/fenofibrate/",
  "context_path": "api/v1/context/cardio--fenofibrate.md"
}
